Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bradley Theodore Hyman, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Bradley Hyman and John Growdon.
Connection Strength

4.750
  1. APOE genotype and brain development. JAMA Neurol. 2014 Jan; 71(1):7-8.
    View in: PubMed
    Score: 0.582
  2. Plasma beta-amyloid linked to cognitive decline. Arch Neurol. 2011 Jun; 68(6):799-801.
    View in: PubMed
    Score: 0.486
  3. Can the immune system fight Alzheimer disease? Nat Med. 2006 Jul; 12(7):755-6; discussion 756.
    View in: PubMed
    Score: 0.346
  4. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann N Y Acad Sci. 1996 Dec 16; 802:1-5.
    View in: PubMed
    Score: 0.179
  5. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996 Aug; 47(2):444-8.
    View in: PubMed
    Score: 0.174
  6. Apolipoprotein E epsilon4/4 in a neuropathologically normal very elderly individual. Arch Neurol. 1996 Mar; 53(3):215.
    View in: PubMed
    Score: 0.169
  7. Massachusetts Alzheimer's Disease Research Center: progress and challenges. Alzheimers Dement. 2015 Oct; 11(10):1241-5.
    View in: PubMed
    Score: 0.163
  8. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014 Apr; 75(4):597-601.
    View in: PubMed
    Score: 0.148
  9. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol. 2013 Jun; 72(6):462-71.
    View in: PubMed
    Score: 0.140
  10. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol. 2013 Jun; 182(6):2332-44.
    View in: PubMed
    Score: 0.139
  11. Stable size distribution of amyloid plaques over the course of Alzheimer disease. J Neuropathol Exp Neurol. 2012 Aug; 71(8):694-701.
    View in: PubMed
    Score: 0.132
  12. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol. 2011 Sep; 179(3):1373-84.
    View in: PubMed
    Score: 0.123
  13. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):220-6.
    View in: PubMed
    Score: 0.114
  14. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010 May; 133(Pt 5):1312-27.
    View in: PubMed
    Score: 0.112
  15. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol. 2007 Nov; 114(5):471-9.
    View in: PubMed
    Score: 0.094
  16. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007 Mar; 64(3):431-4.
    View in: PubMed
    Score: 0.091
  17. No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathol. 2006 Oct; 112(4):439-49.
    View in: PubMed
    Score: 0.086
  18. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol. 2006 Feb; 111(2):101-8.
    View in: PubMed
    Score: 0.084
  19. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry. 2004 Mar-Apr; 12(2):146-56.
    View in: PubMed
    Score: 0.074
  20. ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696.
    View in: PubMed
    Score: 0.057
  21. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020; 10(2):505-510.
    View in: PubMed
    Score: 0.055
  22. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology. 1999 Oct 12; 53(6):1284-91.
    View in: PubMed
    Score: 0.054
  23. Author Correction: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aß, tau, immunity and lipid processing. Nat Genet. 2019 Sep; 51(9):1423-1424.
    View in: PubMed
    Score: 0.054
  24. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aß, tau, immunity and lipid processing. Nat Genet. 2019 03; 51(3):414-430.
    View in: PubMed
    Score: 0.052
  25. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci. 1999; 11(3):336-42.
    View in: PubMed
    Score: 0.051
  26. Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet. 1998 Nov; 7(12):1953-6.
    View in: PubMed
    Score: 0.051
  27. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017 09; 49(9):1373-1384.
    View in: PubMed
    Score: 0.046
  28. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol. 2017 Jan; 81(1):117-128.
    View in: PubMed
    Score: 0.045
  29. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997 Jan; 41(1):17-24.
    View in: PubMed
    Score: 0.045
  30. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996 Jul 15; 16(14):4491-500.
    View in: PubMed
    Score: 0.043
  31. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. Ann N Y Acad Sci. 1996 Jan 17; 777:158-65.
    View in: PubMed
    Score: 0.042
  32. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol. 1996 Jan; 39(1):62-70.
    View in: PubMed
    Score: 0.042
  33. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015 Nov; 78(5):787-800.
    View in: PubMed
    Score: 0.041
  34. Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71.
    View in: PubMed
    Score: 0.041
  35. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol. 2015 Feb; 72(2):209-16.
    View in: PubMed
    Score: 0.039
  36. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol. 2014 Nov; 71(11):1394-404.
    View in: PubMed
    Score: 0.039
  37. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7.
    View in: PubMed
    Score: 0.036
  38. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet. 2012 Dec; 44(12):1349-54.
    View in: PubMed
    Score: 0.034
  39. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology. 2012 Jul 17; 79(3):221-8.
    View in: PubMed
    Score: 0.033
  40. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992 Mar; 42(3 Pt 1):631-9.
    View in: PubMed
    Score: 0.032
  41. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord. 2011 Oct; 26(12):2283-6.
    View in: PubMed
    Score: 0.031
  42. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 May; 43(5):436-41.
    View in: PubMed
    Score: 0.030
  43. Novel progranulin mutation detected in 2 patients with FTLD. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):173-8.
    View in: PubMed
    Score: 0.030
  44. No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2009; 28(5):471-5.
    View in: PubMed
    Score: 0.027
  45. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008 Sep 16; 71(12):903-10.
    View in: PubMed
    Score: 0.025
  46. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009 Mar; 19(3):497-510.
    View in: PubMed
    Score: 0.025
  47. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol. 2008 Jun; 65(6):776-85.
    View in: PubMed
    Score: 0.025
  48. Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study. PLoS One. 2008 Feb 13; 3(2):e1590.
    View in: PubMed
    Score: 0.024
  49. TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol. 2008 Jan; 67(1):62-7.
    View in: PubMed
    Score: 0.024
  50. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis. 2007; 4(6):403-5.
    View in: PubMed
    Score: 0.024
  51. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology. 2005 Nov 08; 65(9):1402-8.
    View in: PubMed
    Score: 0.021
  52. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004 Mar 23; 62(6):925-31.
    View in: PubMed
    Score: 0.018
  53. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003 Jul; 60(7):958-64.
    View in: PubMed
    Score: 0.018
  54. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol. 2000 Nov; 57(11):1579-83.
    View in: PubMed
    Score: 0.015
  55. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1999 Nov; 58(11):1147-55.
    View in: PubMed
    Score: 0.014
  56. Unraveling the mystery of cognitive changes in old age: correlation of neuropsychological evaluation with neuropathological findings in the extreme old. Int Psychogeriatr. 1998 Mar; 10(1):25-41.
    View in: PubMed
    Score: 0.012
  57. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp Neurol. 1998 Jan; 149(1):175-82.
    View in: PubMed
    Score: 0.012
  58. A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol. 1997 Jun; 41(6):809-13.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.